GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

PrimeTradingCorp Oct. 4 at 9:11 PM

$AGAE and $GTBP back in my buy zone. $PAVS Top play and expecting a double. Huge momentum.

0 · Reply

BullseyeStock Oct. 3 at 1:32 AM

GIPR is the type of setup market is loving right now. When more folks finds this, expecting big things! Float is very small on it, so will go up fast! Be early bulls, GIPR has the parabolic look! GIPR ✅Partnerships = increase revenues ✅Go private = They are undervalued currently compared to peers and revenues ✅Joint venture = would increase share price tremendously ✅Sale of the company = they would get probably 4x-5x minimum their yearly revenues. $SAVA $DFLI $GTBP $VERO good list

0 · Reply

MexaTraders Oct. 2 at 9:15 PM

What's happening on ticker ASTC right now?! Are they pumping ASTC for 300% next? Looks like its breaking out! Shorts overextended - Looks like its about to HALT UP and Squeeze any time! Some will buy it now some will chase it later - dont miss ASTC $PALI $GTBP $XRP.X $BTC.X __2

0 · Reply

MexaTraders Oct. 2 at 8:30 PM

Big traders are on ticker ASTC now.. its breaking out.. @TopStockAlerts has over 100,000 Followers on Stocktwits and is on ASTC now! Breaking out now.. ASTC has only 600k shares outstanding People from $PALI $DFLI $GTBP $SPHL are moving to ASTC now.

0 · Reply

Dr_Monkeybreath Oct. 2 at 8:13 PM

$GTBP 😏

1 · Reply

Duskfall Oct. 1 at 6:32 PM

$GTBP Not much but something..

0 · Reply

lookgoodplaygood22 Oct. 1 at 3:48 PM

$GLMD $GNPX $GTBP $PDSB $SGMT gold mine.

0 · Reply

CalculatedSwing Oct. 1 at 3:03 PM

$GLMD 🚀 $GLMD soaring +10% on epic proxy news! CEO Baharaff locked in with equity grants & performance bonuses tied to big milestones—NASH pipeline looking hot! Newbies, this is your chance to go all in for the moon! 🌕 Tagging the degens, leg up time: $SGMT $GTBP $PDSB $GNPX #Biotech #AllIn

1 · Reply

Duskfall Oct. 1 at 2:16 PM

$GTBP 👍

0 · Reply

PrimeTradingCorp Oct. 1 at 3:19 AM

$PAVS Accumulating huge position at this level. News overdue and this will launch to $3 land soon. $GTBP Love the possibility. Waiting for re entry. Also have $AGAE back on w $CETX and $YAAS watching from sideline. Waiting for them to settle

0 · Reply

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 7 weeks ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 13, 2025, 9:00 AM EDT - 4 months ago

GT Biopharma Appoints New Member to its Board of Directors

May 19, 2025, 9:00 AM EDT - 4 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Feb 25, 2025, 2:00 PM EST - 7 months ago

GT Biopharma Announces Exercise of Warrants

Nov 14, 2024, 4:00 PM EST - 11 months ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 26, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 1, 2024, 11:00 AM EST - 1 year ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 1 year ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 1 year ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023, 9:05 AM EDT - 2 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

Mar 30, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 9:00 AM EST - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 2 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Jun 10, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

May 16, 2022, 8:01 AM EDT - 3 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 12, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

Apr 11, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Mar 28, 2022, 4:15 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 21, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Mar 9, 2022, 4:24 PM EST - 3 years ago

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

Mar 3, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

Feb 24, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

Feb 18, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

Jan 20, 2022, 7:30 AM EST - 4 years ago

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

Jan 6, 2022, 4:30 PM EST - 4 years ago

GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PrimeTradingCorp Oct. 4 at 9:11 PM

$AGAE and $GTBP back in my buy zone. $PAVS Top play and expecting a double. Huge momentum.

0 · Reply

BullseyeStock Oct. 3 at 1:32 AM

0 · Reply

MexaTraders Oct. 2 at 9:15 PM

0 · Reply

MexaTraders Oct. 2 at 8:30 PM

0 · Reply

Dr_Monkeybreath Oct. 2 at 8:13 PM

$GTBP 😏

1 · Reply

Duskfall Oct. 1 at 6:32 PM

$GTBP Not much but something..

0 · Reply

lookgoodplaygood22 Oct. 1 at 3:48 PM

$GLMD $GNPX $GTBP $PDSB $SGMT gold mine.

0 · Reply

CalculatedSwing Oct. 1 at 3:03 PM

1 · Reply

Duskfall Oct. 1 at 2:16 PM

$GTBP 👍

0 · Reply

PrimeTradingCorp Oct. 1 at 3:19 AM

0 · Reply

Baazigar30 Sep. 30 at 9:44 PM

$GTBP Watching for entry Big catalyst any day 👇 Looks like next one to big run imo Low floater with high short

0 · Reply

Duskfall Sep. 30 at 2:23 PM

$GTBP The FDA's decision to approve an IND application for GTB-3650 or GTB-5550 is a significant catalyst. Hopefully it will come to fruition.

0 · Reply

Dr_Monkeybreath Sep. 30 at 1:58 PM

$GTBP 6,161 @ .825🍽️

0 · Reply

Dr_Monkeybreath Sep. 30 at 1:43 PM

$GTBP 5,000 @ .88.🔒money for more if it still wants to dip.

0 · Reply

Duskfall Sep. 30 at 1:38 PM

$GTBP Added again 0.57✅

1 · Reply

PAS_Trader Sep. 29 at 8:10 PM

$GTBP first stop .20 c and then 100x reverse split

0 · Reply

leobenucci Sep. 29 at 6:44 PM

$GTBP With this volume it's definitely not a strong hand

0 · Reply

PAS_Trader Sep. 29 at 5:45 PM

$GTBP small investors stay away

0 · Reply

PAS_Trader Sep. 29 at 5:45 PM

$GTBP every 10% up will bring 25% down

0 · Reply

PAS_Trader Sep. 29 at 5:44 PM

$GTBP Trash . Reverse split is coming

0 · Reply

Dr_Monkeybreath Sep. 29 at 5:05 PM

$GTBP i don't use stoplosses.😉

1 · Reply

PAS_Trader Sep. 29 at 4:38 PM

$GTBP someone knows something before small investors.. they might announce something bad soon

0 · Reply

Market Cap	2.27M
Revenue (ttm)	0.00
Net Income (ttm)	-13.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	320,900
Avg Vol	345,100
Day's Range	N/A - N/A
Shares Out	3.56M
Stochastic %K	29%
Beta	1.32
Analysts	Sell
Price Target	$11.00